AMT files request with EMA to re-examine Glybera MAA
AMT has developed Glybera for the treatment of patients who are suffering from genetic disorder lipoprotein lipase deficiency (LPLD). The re-examination of the dossier is expected to be
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.